This Stock is Revolutionizing Healthcare with Non-Invasive Cancer Detection and FDA-Cleared Eye Care Products While Scaling Across the U.S. Market! ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily.
YD Bio Ltd. (NASDAQ: YDES)is Revolutionizing Healthcare with Non-Invasive Cancer Detection and FDA-Cleared Eye Care Products While Scaling Across the U.S. Market!
YD Bio Ltd. (NASDAQ: YDES) is not your typical biotech startup — it's a commercial-stage powerhouse delivering innovative solutions in early cancer detection and ocular health. With FDA-cleared eye care products already on the market and the OkaiDx™ blood-based diagnostics platform expanding to pancreatic and colorectal cancer detection in 44 U.S. states, YDES is actively transforming the future of healthcare. Operating through a CAP-accredited, CLIA-certified U.S. laboratory and supported by a nationwide telehealth network, the company is making precision diagnostics more accessible than ever. YDES' strategic partnerships with EG Biomed and 3D Global Biotech provide long-term access to cutting-edge diagnostics and regenerative eye therapies, creating a diversified platform that spans multiple high-growth markets. By combining revenue-generating commercial operations with an ambitious pipeline in regenerative medicine, YDES is positioned for scalable impact in global healthcare. From early cancer detection to advanced ocular therapies, the company is turning scientific innovation into real-world solutions for patients and providers alike. YDES is one of the few biotech companies that's already moving from lab innovation to market execution. With a U.S. expansion underway, OkaiDx™ testing in 44 states, FDA-cleared eye care products, and a strong patent portfolio, YDES is positioned to scale rapidly in 2026. Investors and healthcare leaders should watch closely as YD Bio turns cutting-edge science into tangible patient solutions. Learn how YDES is turning groundbreaking science into real-world healthcare solutions. |
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of YD Bio Ltd. (NASDAQ: YDES). The compensation consists of up to $6,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser YD Bio Ltd. (NASDAQ: YDES) and we are not responsible for any errors or omissions in any information provided about the securities of YD Bio Ltd. (NASDAQ: YDES) or Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 1/7/2026. Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.
|
|
No comments:
Post a Comment